ALRN Aileron Therapeutics Inc

Price (delayed)

$3.18

Market cap

$68.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.22

Enterprise value

$56.59M

Aileron Therapeutics Inc. is a clinical-stage biopharmaceutical company that is focused on enabling patients to fight cancer without the fear or burden of chemotherapy-induced side effects. The company believes selective ...

Highlights
The debt has dropped by 100% since the previous quarter
The EPS is up by 38% year-on-year and by 6% since the previous quarter
Aileron Therapeutics's net income has increased by 24% YoY but it has decreased by 15% from the previous quarter
ALRN's quick ratio has shrunk by 54% YoY and by 33% QoQ
Aileron Therapeutics's equity has decreased by 7% QoQ

Key stats

What are the main financial stats of ALRN
Market
Shares outstanding
21.59M
Market cap
$68.65M
Enterprise value
$56.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$18.07M
EBITDA
-$17.93M
Free cash flow
-$20.38M
Per share
EPS
-$3.22
Free cash flow per share
-$2.45
Book value per share
$20.11
Revenue per share
$0
TBVPS
$1.65
Balance sheet
Total assets
$99.19M
Total liabilities
$7.86M
Debt
$0
Equity
$91.33M
Working capital
$8.23M
Liquidity
Debt to equity
0
Current ratio
2.82
Quick ratio
2.66
Net debt/EBITDA
0.67
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-31.1%
Return on equity
-33.8%
Return on invested capital
N/A
Return on capital employed
-19.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ALRN stock price

How has the Aileron Therapeutics stock price performed over time
Intraday
2.91%
1 week
10.8%
1 month
-2.15%
1 year
60.35%
YTD
4.31%
QTD
14.8%

Financial performance

How have Aileron Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$18.47M
Net income
-$18.07M
Gross margin
N/A
Net margin
N/A
Aileron Therapeutics's net income has increased by 24% YoY but it has decreased by 15% from the previous quarter
The operating income has increased by 24% year-on-year but it has declined by 13% since the previous quarter

Growth

What is Aileron Therapeutics's growth rate over time

Valuation

What is Aileron Therapeutics stock price valuation
P/E
N/A
P/B
0.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 38% year-on-year and by 6% since the previous quarter
ALRN's P/B is 88% below its 5-year quarterly average of 1.3 and 60% below its last 4 quarters average of 0.4
Aileron Therapeutics's equity has decreased by 7% QoQ

Efficiency

How efficient is Aileron Therapeutics business performance
The ROE has soared by 70% YoY and by 27% from the previous quarter
The ROA has soared by 67% YoY and by 26% from the previous quarter

Dividends

What is ALRN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ALRN.

Financial health

How did Aileron Therapeutics financials performed over time
The total liabilities has soared by 172% YoY
ALRN's quick ratio has shrunk by 54% YoY and by 33% QoQ
The debt is 100% smaller than the equity
The debt has dropped by 100% since the previous quarter
Aileron Therapeutics's equity has decreased by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.